

Notice from the Executive Officer: Funding of enoxaparin under the Ontario Drug Benefit Program

May 5, 2021

Redesca and Redesca HP (enoxaparin) were approved by Health Canada as biosimilar versions of enoxaparin. The originator versions of enoxaparin are Lovenox® and Lovenox® HP. Biosimilars are not identical to originator biologics. However, Health Canada conducts rigorous testing to ensure that biosimilars have a highly similar structure, are equally as safe, and have the same therapeutic effect as an originator biologic. Biosimilars also present an opportunity to achieve better value for money for biologic drugs that will help to support the long-term sustainability and accessibility of Ontario's public drug programs.

Effective with the April 2021 Ontario Drug Benefit (ODB) Formulary update (April 30, 2021), changes to funding of enoxaparin on the ODB Program will be as follows:

- Some Redesca products will be listed on the ODB Formulary/Comparative Drug Index (Formulary) as General Benefits.

In view of implementation considerations and ongoing COVID-19 priorities in Ontario, the funding status of Lovenox products on the ODB Formulary and under the Exceptional Access Program (EAP) will remain unchanged at this time. Further changes to the funding status of Lovenox products will be announced at a later date.

Details of the funding of Redesca products will also be posted in the April 2021 Formulary update which can be found on the ministry's website at:

http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx

To further inform healthcare providers and patients, we have also included a Frequently Asked Questions (FAQs) document for reference purposes.

Additional information:

For pharmacies:

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

For all other health care providers and the public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559.
In Toronto, TTY 416-327-4282.